Carillon Tower Advisers Inc. reduced its stake in Cooper Companies Inc (NYSE:COO) by 17.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,380 shares of the medical device company’s stock after selling 1,920 shares during the quarter. Carillon Tower Advisers Inc.’s holdings in Cooper Companies were worth $2,786,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Flagship Harbor Advisors LLC lifted its position in Cooper Companies by 62.5% in the 2nd quarter. Flagship Harbor Advisors LLC now owns 78 shares of the medical device company’s stock valued at $26,000 after acquiring an additional 30 shares in the last quarter. World Asset Management Inc lifted its position in Cooper Companies by 1.2% in the 2nd quarter. World Asset Management Inc now owns 2,744 shares of the medical device company’s stock valued at $924,000 after acquiring an additional 32 shares in the last quarter. Signaturefd LLC lifted its position in Cooper Companies by 3.8% in the 2nd quarter. Signaturefd LLC now owns 875 shares of the medical device company’s stock valued at $295,000 after acquiring an additional 32 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Cooper Companies by 0.4% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,282 shares of the medical device company’s stock valued at $3,464,000 after acquiring an additional 38 shares in the last quarter. Finally, Advisory Services Network LLC lifted its position in Cooper Companies by 13.6% in the 2nd quarter. Advisory Services Network LLC now owns 318 shares of the medical device company’s stock valued at $107,000 after acquiring an additional 38 shares in the last quarter. 94.42% of the stock is currently owned by hedge funds and other institutional investors.

Shares of COO opened at $296.77 on Thursday. The firm has a market cap of $14.65 billion, a PE ratio of 25.81, a P/E/G ratio of 2.14 and a beta of 0.90. The company has a current ratio of 1.29, a quick ratio of 0.73 and a debt-to-equity ratio of 0.39. The firm has a fifty day simple moving average of $291.48 and a two-hundred day simple moving average of $309.87. Cooper Companies Inc has a 1-year low of $228.65 and a 1-year high of $344.32.

Cooper Companies (NYSE:COO) last announced its earnings results on Thursday, August 29th. The medical device company reported $3.23 earnings per share for the quarter, beating analysts’ consensus estimates of $3.16 by $0.07. The business had revenue of $679.40 million during the quarter, compared to analyst estimates of $687.60 million. Cooper Companies had a net margin of 17.08% and a return on equity of 17.15%. The company’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same period in the previous year, the business earned $3.00 EPS. As a group, research analysts forecast that Cooper Companies Inc will post 12.32 EPS for the current fiscal year.

Several equities analysts recently issued reports on the company. Wells Fargo & Co upped their price objective on Cooper Companies from $356.00 to $365.00 and gave the company an “outperform” rating in a research report on Thursday, August 8th. Piper Jaffray Companies set a $360.00 price objective on Cooper Companies and gave the company a “buy” rating in a research report on Friday, August 30th. KeyCorp lowered their price objective on Cooper Companies from $351.00 to $348.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. ValuEngine cut Cooper Companies from a “buy” rating to a “hold” rating in a research report on Tuesday, September 10th. Finally, Raymond James reaffirmed a “buy” rating on shares of Cooper Companies in a research report on Monday, August 26th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $326.00.

In other news, Director Allan E. Rubenstein sold 1,335 shares of the company’s stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $299.61, for a total value of $399,979.35. Following the completion of the sale, the director now directly owns 3,591 shares in the company, valued at approximately $1,075,899.51. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.70% of the stock is currently owned by insiders.

Cooper Companies Profile

The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.

Featured Article: Channel Trading

Want to see what other hedge funds are holding COO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cooper Companies Inc (NYSE:COO).

Institutional Ownership by Quarter for Cooper Companies (NYSE:COO)

Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.